Repeated greater occipital nerve injections with corticosteroids in medically intractable chronic cluster headache: a retrospective study
Autor: | Rolf Fronczek, Roy Meilof, Patty G. G. Doesborg, Michel D. Ferrari, Ilse F. de Coo, Eveline C. Bartels, Roemer B. Brandt |
---|---|
Rok vydání: | 2021 |
Předmět: |
medicine.medical_specialty
Neurology Nerve block Greater occipital nerve medicine.medical_treatment Pain Cluster Headache Dermatology 03 medical and health sciences 0302 clinical medicine Adrenal Cortex Hormones Humans Medicine 030212 general & internal medicine Retrospective Studies Neuromodulation business.industry Medical record Cluster headache Retrospective cohort study General Medicine medicine.disease Psychiatry and Mental health Spinal Nerves Treatment Outcome Tolerability Anesthesia Original Article Neurology (clinical) Neurosurgery business Prophylactic treatment 030217 neurology & neurosurgery |
Zdroj: | Neurological Sciences Neurological Sciences, 43, 1267-1272. SPRINGER-VERLAG ITALIA SRL |
ISSN: | 1590-3478 1590-1874 |
Popis: | Introduction Current prophylactic drugs for cluster headache are associated with limited efficacy, serious side effects and poor tolerability. Greater occipital nerve injection (GON-injection) has been proven effective and safe as a single, one-time injection in episodic (ECH), and to a lesser extent, chronic cluster headache (CCH). We aim to analyse the effectiveness and safety of repeated GON-injections in medically intractable chronic cluster headache (MICCH). Methods Clinical data of all cluster headache patients who had received at least one GON-injection between 2014 and 2018 in our tertiary headache centre were retrieved from patients’ medical records. Clinical history was taken as part of routine care shortly before and 6 weeks after GON-injection. Results We identified 47 MICCH patients (79 injections), and compared results with 22 non-MI CCH patients (30 injections) and 50 ECH patients (63 injections). Nineteen MICCH patients received repeated injections (32 in total, range 2–8). Rates of clinical relevant improvement to a first injection were similar in all groups (MICCH: 60%, non-MICCH 73%, ECH 76%; attack freedom: MICCH: 30%, non-MICCH 32%, ECH 43%). Furthermore, no difference in response to the first and second injection was shown between groups (all p > 0.29). Median effect duration in MICCH was 6 weeks (IQR 2.8–12 weeks). Side effects were only mild and local. Conclusion In this retrospective analysis, first and repeated GON-injections were well-tolerated and equally effective in MICCH as in non-MICCH, and ECH. |
Databáze: | OpenAIRE |
Externí odkaz: |